Anti-Rotavirus (ROTA-3868)

Leinco Technologies
Product Code: LEI-R172
Product Group: Primary Antibodies
CodeSizePrice
LEI-R172-250ug250 ug£434.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Mouse
Antibody Isotype: Mouse IgG2b
Antibody Clonality: Monoclonal
Antibody Clone: ROTA-3868
Regulatory Status: RUO
Target Species: Rotavirus
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Lateral-Flow Immunochromatographic Assay
Shipping:
2 - 8°C Wet Ice
Storage:
This purified antibody is stable when stored at 2-8°C. Do not freeze.

Further Information

Concentration:
?1.0 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
Formulated in 0.01 M phosphate buffered saline, pH 7.2 and contains 0.1% sodium azide. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
Formulated in 0.01 M phosphate buffered saline, pH 7.2 and contains 0.1% sodium azide. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Long Description:
Rotavirus is a highly contagious, double-stranded RNA virus that is the leading cause of severe gastroenteritis in infants and young children worldwide. It belongs to the Reoviridae family and is classified into different serotypes based on the antigenic properties of its outer protein coat. Rotavirus spreads primarily through the fecal-oral route, either by direct contact with an infected person or by consuming contaminated food or water. The virus replicates in the small intestine, leading to the destruction of the intestinal epithelial cells, which results in diarrhea, vomiting, fever, and dehydration. Rotavirus infections are particularly dangerous in developing countries with limited access to proper sanitation and healthcare, where they contribute significantly to childhood morbidity and mortality. Vaccination against rotavirus has shown to be highly effective in reducing severe rotavirus infections and associated hospitalizations.
Purity:
?90%
Target:
Rotavirus

References

1. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. Link